10-Q: United-Guardian Q3 Net Income Plunges 69% Amid China Slowdown

United-Guardian, Inc. reported a significant decline in net sales and net income for Q3 2025, primarily driven by a sharp drop in cosmetic ingredient sales to China.

Summary

• Net sales for the third quarter of 2025 decreased by $795,852 (26%) to $2,264,261 compared to $3,060,113 in Q3 2024.
• Net income for the third quarter of 2025 fell by $597,043 (69%) to $268,441 from $865,484 in Q3 2024.
• Earnings per common share (Basic and Diluted) for Q3 2025 were $0.06, down from $0.19 in Q3 2024.
• For the first nine months of 2025, net sales decreased by $2,121,649 (22%) to $7,583,613 compared to $9,705,262 in the same period of 2024.
• Net income for the first nine months of 2025 decreased by $1,290,989 (47%) to $1,456,162 from $2,747,151 in the first nine months of 2024.
• Cosmetic ingredient sales for the first nine months of 2025 decreased by $2,586,495 (56%) to $1,998,948, primarily due to softer economic conditions in China, tariffs, geopolitical concerns, and a major distributor (ASI) working off excess inventory.
• Pharmaceutical sales for the first nine months of 2025 increased by $362,480 (10%) to $3,848,474, mainly driven by increased gross sales of Renacidin.
• Medical lubricant sales for the first nine months of 2025 increased by $102,366 (6%) to $1,736,191, primarily due to increased orders from two customers in China.
• Cost of sales as a percentage of sales increased to 58% in Q3 2025 (from 46% in Q3 2024) and to 50% for the first nine months of 2025 (from 47% in 2024), attributed to a higher proportion of lower-margin pharmaceutical sales and decreased cosmetic product production.
• Operating expenses increased by 5% for Q3 2025 and 10% for the first nine months of 2025, mainly due to increases in sales and marketing, Board of Directors fees, consulting fees, and payroll expenses.
• Investment income decreased by 25% for Q3 2025 and 23% for the first nine months of 2025, due to lower interest rates and a decrease in the average amount invested.
• Manufacturing and sales of the new Natrajel line of sexual wellness ingredients, expected to begin in 2025, have been delayed until 2026 due to customer launch timelines.
• Working capital decreased by $1,102,098 to $9,648,984 at September 30, 2025, from $10,751,082 at December 31, 2024, while the current ratio improved from 6.6 to 1 to 7.0 to 1.

Sentiment

Score: 3

Explanation: The company experienced significant declines in net sales and net income, particularly in its cosmetic ingredients segment due to external market pressures and tariffs. A key new product launch is delayed. While there are some positive developments in other segments and a strong liquidity position, the overall financial performance for the period is substantially negative.

Positives

• Pharmaceutical sales increased by 10% for the nine months ended September 30, 2025, driven by Renacidin.
• Medical lubricant sales increased by 6% for the nine months ended September 30, 2025, due to increased orders from China.
• The current ratio improved to 7.0 to 1 at September 30, 2025, from 6.6 to 1 at December 31, 2024, indicating strong liquidity.
• Expanded distribution network with Azelis Group NV to include medical products in the UK and Ireland, and personal care products in South Korea.
• Initiated a payer outreach program for Renacidin, receiving positive feedback on its value proposition, aiming to broaden awareness and grow market share.

Negatives

• Net sales decreased significantly by 26% for the three months and 22% for the nine months ended September 30, 2025.
• Net income plunged by 69% for the three months and 47% for the nine months ended September 30, 2025.
• Earnings per common share decreased by 68.4% for the three months and 46.7% for the nine months ended September 30, 2025.
• Cosmetic ingredient sales decreased by 69% for the three months and 56% for the nine months ended September 30, 2025, primarily due to economic conditions in China, tariffs, and distributor inventory adjustments.
• Cost of sales as a percentage of sales increased due to a higher proportion of lower-margin pharmaceutical sales and higher per-unit overhead costs from decreased cosmetic product production.
• Investment income decreased by 25% for the three months and 23% for the nine months ended September 30, 2025, due to lower interest rates and reduced average investment amounts.
• Manufacturing and sales of the new Natrajel line of sexual wellness ingredients have been delayed from 2025 to 2026 due to customer launch timeline.

Risks

• Global supply chain instability, inflation, and tariffs, particularly those imposed on imports from China, could materially and adversely affect business, financial condition, or results of operations.
• Tariffs may make products less cost-competitive and reduce gross margins, especially in China, where there is significant competition from Asian companies.
• Inability to increase product prices sufficiently to offset tariffs could reduce demand in certain regions.
• Tariffs on finished products manufactured in China and imported into the U.S. could increase prices and impact demand for those products.
• Customers may consider moving manufacturing from China as a strategic decision to limit the impact from tariffs.
• Concentration of credit risk with a relatively small number of customers; a significant change in the liquidity or financial position of any major customer could significantly impact results.
• Supplier concentration risk with three major raw material suppliers accounting for approximately 79% of raw material purchases for the nine months ended September 30, 2025.
• Reliance on one contract manufacturer for the pharmaceutical product Renacidin; any disruption in their operations could materially impact the revenue stream.

Future Outlook

The company hopes to see a turnaround in cosmetic ingredient sales with additional price support for customers. It plans to continue broadening the awareness of Renacidin through a payer outreach program to grow market share. Manufacturing and sales of the new Natrajel line of sexual wellness ingredients are now expected to begin in 2026. The company expects to continue using its cash for dividend payments, purchasing marketable securities, and pursuing growth opportunities. Final payments for the building sprinkler system upgrade are expected in the fourth quarter of 2025.

Management Comments

• "We had expected to begin manufacturing and reporting sales of this new line of products in 2025, but manufacturing has been delayed until 2026 due to customer launch timeline."
• "With price support ASI has regained some customers, and we hope to see a turnaround in sales moving forward."
• "We will continue to broaden the awareness of Renacidin with the goal of growing our market share."
• "The Company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of growth opportunities that are in the best interest of the Company and its shareholders."

Industry Context

The company's performance is significantly impacted by global trade policies, particularly tariffs between the U.S. and China, which have softened demand for cosmetic ingredients in China. The pharmaceutical segment is navigating changes in government rebate programs, such as the new Medicare Part D Manufacturer Discount Program, which is expected to increase rebate liabilities for drug manufacturers over time. The company faces significant competition from Asian companies in the Chinese market for its cosmetic products.

Comparison to Industry Standards

• The company's return policies for pharmaceutical products are in conformance with standard pharmaceutical industry practice.
• In China, the company faces significant competition from Asian companies that manufacture and sell products competitive with its cosmetic ingredients.

Corporate Governance

Related Party Transactions

• Payments of $9,640 for the three months and $13,640 for the nine months ended September 30, 2025, were made to PKF OConnor Davies (PKF) for accounting and tax services. Lawrence Maietta, a partner at PKF, is a director of the Company.

Stakeholder Impact

• Shareholders: Experienced significant declines in earnings per share, but the company continues to pay dividends and has a strong current ratio. Future growth initiatives and market recovery could positively impact shareholder value.
• Employees: Operating expenses and R&D expenses increased due to higher payroll and payroll-related expenses, indicating continued investment in human capital. The company also makes contributions to a 401(k) defined contribution plan.
• Customers: Customers for cosmetic ingredients, particularly in China, face price issues due to tariffs, potentially leading to reduced demand or seeking lower-cost alternatives. The launch of the new Natrajel line is delayed, impacting customers awaiting these products.
• Suppliers: The company has concentration risk with three major raw material suppliers and one contract manufacturer for Renacidin, making it vulnerable to disruptions in their operations or supply chains.
• Creditors: The company maintains a strong current ratio of 7.0 to 1 and sufficient working capital, indicating a healthy ability to meet short-term obligations.

Next Steps

• Begin manufacturing and reporting sales of the new Natrajel line of sexual wellness ingredients in 2026.
• Continue the payer outreach program to broaden awareness of Renacidin and grow market share.
• Closely monitor the supply chain to control costs.
• Expand the distribution network to better serve customers.
• Seek opportunities to expand the position in healthcare.
• Pursue external opportunities to grow the business.
• Make final payments for the building sprinkler system upgrade during the fourth quarter of 2025.

Key Dates

Recommendation

Despite significant declines in net sales and net income, the company maintains a strong current ratio of 7.0 to 1 and continues to pay dividends. Strategic initiatives, including expanding distribution and a new product line (Natrajel) expected in 2026, offer future potential. However, current performance is negatively impacted by external factors like tariffs and economic slowdown in China, and a key product launch is delayed. The stock is a 'hold' as investors await the impact of these strategic efforts and a potential recovery in key markets.

Keywords

United-Guardian, UG, 10-Q, Q3 2025, financial results, cosmetic ingredients, pharmaceuticals, medical lubricants, sexual wellness, Natrajel, tariffs, China, supply chain, earnings, revenue, net income, SEC filing, corporate governance, risk factors